NeoGenomics, Inc. (NEO)
USD 7.7
(6.06%)
USD 7.7
(6.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -87.96 Million USD | 39.02% |
| 2022 | -144.25 Million USD | -1628.17% |
| 2021 | -8.34 Million USD | -300.07% |
| 2020 | 4.17 Million USD | -47.89% |
| 2019 | 8 Million USD | 203.26% |
| 2018 | 2.64 Million USD | 412.06% |
| 2017 | -846 Thousand USD | 85.22% |
| 2016 | -5.72 Million USD | -125.76% |
| 2015 | -2.53 Million USD | -323.94% |
| 2014 | 1.13 Million USD | -44.32% |
| 2013 | 2.03 Million USD | 3027.69% |
| 2012 | 65 Thousand USD | 105.52% |
| 2011 | -1.17 Million USD | 64.37% |
| 2010 | -3.3 Million USD | -47.27% |
| 2009 | -2.24 Million USD | -62.22% |
| 2008 | -1.38 Million USD | 59.1% |
| 2007 | -3.38 Million USD | -2506.93% |
| 2006 | -129.66 Thousand USD | 87.0% |
| 2005 | -997.16 Thousand USD | -21.76% |
| 2004 | -818.98 Thousand USD | -52.86% |
| 2003 | -535.76 Thousand USD | 9.27% |
| 2002 | -590.52 Thousand USD | 92.69% |
| 2001 | -8.07 Million USD | -732.54% |
| 2000 | -970.28 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -18.64 Million USD | 31.11% |
| 2024 Q3 | -17.69 Million USD | 5.06% |
| 2024 Q1 | -27.06 Million USD | -88.89% |
| 2023 Q3 | -18.51 Million USD | 23.9% |
| 2023 Q4 | -14.32 Million USD | 22.63% |
| 2023 FY | -87.96 Million USD | 39.02% |
| 2023 Q1 | -30.79 Million USD | -35.74% |
| 2023 Q2 | -24.33 Million USD | 20.99% |
| 2022 Q3 | -36.85 Million USD | -4.39% |
| 2022 Q1 | -49.4 Million USD | -18.32% |
| 2022 Q4 | -22.68 Million USD | 38.44% |
| 2022 FY | -144.25 Million USD | -1628.17% |
| 2022 Q2 | -35.3 Million USD | 28.55% |
| 2021 Q1 | -22.11 Million USD | -243.44% |
| 2021 Q2 | 75.87 Million USD | 443.1% |
| 2021 Q4 | -41.75 Million USD | -105.22% |
| 2021 FY | -8.34 Million USD | -300.07% |
| 2021 Q3 | -20.34 Million USD | -126.82% |
| 2020 Q4 | 15.41 Million USD | 502.93% |
| 2020 Q2 | -6.82 Million USD | 2.21% |
| 2020 Q1 | -6.97 Million USD | -210.83% |
| 2020 FY | 4.17 Million USD | -47.89% |
| 2020 Q3 | 2.55 Million USD | 137.47% |
| 2019 Q4 | 6.29 Million USD | 193.79% |
| 2019 Q3 | 2.14 Million USD | 7.63% |
| 2019 Q2 | 1.99 Million USD | 182.14% |
| 2019 Q1 | -2.42 Million USD | -786.69% |
| 2019 FY | 8 Million USD | 203.26% |
| 2018 Q1 | 644 Thousand USD | -86.99% |
| 2018 Q2 | -380 Thousand USD | -159.01% |
| 2018 Q3 | 2.02 Million USD | 632.37% |
| 2018 Q4 | 353 Thousand USD | -82.55% |
| 2018 FY | 2.64 Million USD | 412.06% |
| 2017 Q3 | -5.1 Million USD | -11760.47% |
| 2017 FY | -846 Thousand USD | 85.22% |
| 2017 Q4 | 4.95 Million USD | 197.08% |
| 2017 Q2 | -43 Thousand USD | 93.43% |
| 2017 Q1 | -654 Thousand USD | 89.49% |
| 2016 Q3 | -67 Thousand USD | -116.22% |
| 2016 FY | -5.72 Million USD | -125.76% |
| 2016 Q1 | 155 Thousand USD | 110.52% |
| 2016 Q2 | 413 Thousand USD | 166.45% |
| 2016 Q4 | -6.22 Million USD | -9188.06% |
| 2015 Q1 | -761 Thousand USD | -172.68% |
| 2015 Q4 | -1.47 Million USD | -1078.4% |
| 2015 Q3 | -125 Thousand USD | 28.98% |
| 2015 FY | -2.53 Million USD | -323.94% |
| 2015 Q2 | -176 Thousand USD | 76.87% |
| 2014 Q4 | 1.04 Million USD | 459.79% |
| 2014 FY | 1.13 Million USD | -44.32% |
| 2014 Q1 | 102 Thousand USD | -88.1% |
| 2014 Q2 | 274 Thousand USD | 168.63% |
| 2014 Q3 | -291 Thousand USD | -206.2% |
| 2013 Q3 | 900 Thousand USD | 229.67% |
| 2013 Q2 | 273 Thousand USD | 9000.0% |
| 2013 Q1 | 3000.00 USD | 102.65% |
| 2013 FY | 2.03 Million USD | 3027.69% |
| 2013 Q4 | 857 Thousand USD | -4.78% |
| 2012 Q1 | 603 Thousand USD | 296.71% |
| 2012 FY | 65 Thousand USD | 105.52% |
| 2012 Q4 | -113 Thousand USD | 88.41% |
| 2012 Q2 | 551 Thousand USD | -8.62% |
| 2012 Q3 | -975 Thousand USD | -276.95% |
| 2011 Q2 | -293 Thousand USD | 67.19% |
| 2011 FY | -1.17 Million USD | 64.37% |
| 2011 Q3 | -143 Thousand USD | 51.19% |
| 2011 Q4 | 152 Thousand USD | 206.29% |
| 2011 Q1 | -893 Thousand USD | -136.87% |
| 2010 Q4 | -377 Thousand USD | 68.53% |
| 2010 FY | -3.3 Million USD | -47.27% |
| 2010 Q3 | -1.19 Million USD | -22.49% |
| 2010 Q1 | -750 Thousand USD | 50.94% |
| 2010 Q2 | -978 Thousand USD | -30.4% |
| 2009 FY | -2.24 Million USD | -62.22% |
| 2009 Q3 | -755.3 Thousand USD | -9471.03% |
| 2009 Q4 | -1.52 Million USD | -102.4% |
| 2009 Q1 | 33.17 Thousand USD | 103.34% |
| 2009 Q2 | 8060.00 USD | -75.71% |
| 2008 Q2 | 72.27 Thousand USD | 127.24% |
| 2008 FY | -1.38 Million USD | 59.1% |
| 2008 Q4 | -994.37 Thousand USD | -409.61% |
| 2008 Q3 | -195.12 Thousand USD | -369.97% |
| 2008 Q1 | -265.36 Thousand USD | 83.37% |
| 2007 Q1 | -219.54 Thousand USD | 48.85% |
| 2007 Q3 | -591.26 Thousand USD | 39.26% |
| 2007 Q4 | -1.59 Million USD | -169.91% |
| 2007 FY | -3.38 Million USD | -2506.93% |
| 2007 Q2 | -973.5 Thousand USD | -343.42% |
| 2006 Q4 | -429.24 Thousand USD | -1445.81% |
| 2006 FY | -129.66 Thousand USD | 87.0% |
| 2006 Q3 | 31.89 Thousand USD | -80.22% |
| 2006 Q2 | 161.25 Thousand USD | 51.51% |
| 2006 Q1 | 106.43 Thousand USD | 129.51% |
| 2005 FY | -997.16 Thousand USD | -21.76% |
| 2005 Q1 | -215.17 Thousand USD | 30.54% |
| 2005 Q4 | -360.69 Thousand USD | -50.33% |
| 2005 Q3 | -239.93 Thousand USD | -32.3% |
| 2005 Q2 | -181.35 Thousand USD | 15.72% |
| 2004 Q3 | -170.85 Thousand USD | -1.25% |
| 2004 Q2 | -168.74 Thousand USD | 0.51% |
| 2004 FY | -818.98 Thousand USD | -52.86% |
| 2004 Q1 | -169.6 Thousand USD | -17.74% |
| 2004 Q4 | -309.77 Thousand USD | -81.31% |
| 2003 Q1 | -114.8 Thousand USD | -107.85% |
| 2003 Q4 | -144.04 Thousand USD | -4.3% |
| 2003 FY | -535.76 Thousand USD | 9.27% |
| 2003 Q3 | -138.11 Thousand USD | 0.49% |
| 2003 Q2 | -138.79 Thousand USD | -20.9% |
| 2002 Q4 | 1.46 Million USD | 299.78% |
| 2002 Q1 | -580.84 Thousand USD | 91.97% |
| 2002 Q3 | -732.19 Thousand USD | 1.09% |
| 2002 FY | -590.52 Thousand USD | 92.69% |
| 2002 Q2 | -740.24 Thousand USD | -27.44% |
| 2001 Q2 | -214.59 Thousand USD | 37.77% |
| 2001 Q4 | -7.22 Million USD | -2398.48% |
| 2001 Q1 | -344.82 Thousand USD | -45.86% |
| 2001 Q3 | -289.34 Thousand USD | -34.83% |
| 2001 FY | -8.07 Million USD | -732.54% |
| 2000 Q2 | -216.97 Thousand USD | -31.0% |
| 2000 Q3 | -351.26 Thousand USD | -61.89% |
| 2000 Q4 | -236.41 Thousand USD | 32.7% |
| 2000 FY | -970.28 Thousand USD | 0.0% |
| 2000 Q1 | -165.62 Thousand USD | 0.0% |
| 1999 Q1 | -99.04 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 0.58% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -784.362% |
| Aspira Women's Health Inc. | -16.69 Million USD | -427.07% |
| Biodesix, Inc. | -52.14 Million USD | -68.696% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -3246.008% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -1008.327% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -1008.327% |
| Bionano Genomics, Inc. | -232.49 Million USD | 62.163% |
| CareDx, Inc | -190.28 Million USD | 53.77% |
| Check-Cap Ltd. | -17.56 Million USD | -400.729% |
| Castle Biosciences, Inc. | -57.46 Million USD | -53.078% |
| DarioHealth Corp. | -59.42 Million USD | -48.027% |
| Exact Sciences Corporation | -204.14 Million USD | 56.91% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 47.583% |
| Guardant Health, Inc. | -479.44 Million USD | 81.652% |
| ICON Public Limited Company | 612.33 Million USD | 114.366% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 110.41% |
| Illumina, Inc. | -1.16 Billion USD | 92.423% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -766.103% |
| iSpecimen Inc. | -11.09 Million USD | -692.541% |
| Standard BioTools Inc. | -74.65 Million USD | -17.831% |
| MDxHealth SA | -43.1 Million USD | -104.102% |
| 23andMe Holding Co. | -666.7 Million USD | 86.806% |
| Medpace Holdings, Inc. | 282.81 Million USD | 131.105% |
| Myriad Genetics, Inc. | -112 Million USD | 21.457% |
| Mainz Biomed B.V. | -26.29 Million USD | -234.533% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -774.412% |
| Neogen Corporation | -9.42 Million USD | -833.744% |
| Inotiv, Inc. | -105.14 Million USD | 16.333% |
| Natera, Inc. | -434.8 Million USD | 79.768% |
| OPKO Health, Inc. | -188.86 Million USD | 53.422% |
| Psychemedics Corporation | -4.15 Million USD | -2017.67% |
| Prenetics Global Limited | -62.72 Million USD | -40.246% |
| Prenetics Global Limited | -62.72 Million USD | -40.246% |
| Precipio, Inc. | -5.85 Million USD | -1402.956% |
| Personalis, Inc. | -108.29 Million USD | 18.771% |
| RadNet, Inc. | 3.04 Million USD | 2989.882% |
| Sera Prognostics, Inc. | -36.24 Million USD | -142.724% |
| Sotera Health Company | 51.37 Million USD | 271.224% |
| Neuronetics, Inc. | -30.18 Million USD | -191.391% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -5582.687% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -5582.687% |
| Trinity Biotech plc | -24.01 Million USD | -266.259% |
| Twist Bioscience Corporation | -208.72 Million USD | 57.855% |
| Exagen Inc. | -23.68 Million USD | -271.345% |